Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All to Target: Lantus + Apidra vs Novolog Mix in T2DM
NCT00384085Phase 4Completed
- Sponsor
- Sanofi
- Start
- May 2006
- Primary completion
- Mar 2010
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine and insulin glulisine in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Sanofi. Primary endpoints: Percentage of Patients Achieving Glycosylated Hemoglobin A1c < 7.0% at 60 weeks and Change From Baseline in Glycosylated Hemoglobin A1c at 60 weeks. Started May 2006; status: completed.
02
Drugs
insulin glargineinsulin glulisine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00384085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384085.